[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Children's Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":252},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,73,95,124,151,172,193,212,234],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100630519","letermovir-prophylaxis-in-children-with-ebv-positive-tnk-cell-lymphoproliferative-disease-and-refractoryrelapsed-ebv-associated-hemophagocytic-lymphohistiocytosis-100630519",false,"NCT07488728","Letermovir Prophylaxis in Children With EBV-Positive T\u002FNK-Cell Lymphoproliferative Disease and Refractory\u002FRelapsed EBV-Associated Hemophagocytic Lymphohistiocytosis","Impact of Letermovir Prophylaxis on Viral Infections After Allogeneic Hematopoietic Stem Cell Transplantation in Children With EBV-Positive T\u002FNK-Cell Lymphoproliferative Disease and Refractory\u002FRelapsed EBV-Associated Hemophagocytic Lymphohistiocytosis","Inclusion Criteria:\n\n* Diagnosed with EBV-positive T\u002FNK lymphoproliferative disease (EBV-T\u002FNK LPD) according to ICC 2022 criteria, or diagnosed with refractory\u002Frelapsed EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) according to the 2004-HLH diagnostic criteria;\n* Undergoing first allogeneic hematopoietic stem cell transplantation (allo-HSCT) at the study center;\n* Age \\\u003C 18 years;\n* CMV seropositive (IgG+) prior to transplantation;\n* Presence of at least one high-risk factor for CMV infection: haploidentical transplantation, HLA-mismatched transplantation, receipt of ATG (including ATLG\u002FALG) in conditioning, sustained corticosteroid use post-conditioning, donor\u002Frecipient CMV serostatus mismatch, or positive NGS result pre-transplant.\n\nExclusion Criteria:\n\n* History of CMV end-organ disease within 6 months prior to enrollment;\n* Severe hepatic dysfunction (defined as Child-Pugh Class C);\n* End-stage renal impairment with creatinine clearance \\\u003C 10 mL\u002Fmin (calculated by Cockcroft-Gault equation);\n* Prior allogeneic hematopoietic stem cell transplantation;\n* Expected survival ≤ 3 months;\n* Received radiation therapy during conditioning;\n* Initiation of letermovir prophylaxis after day 28 post-transplant;\n* Letermovir dosage or administration not in accordance with the prescribing information;\n* Lack of signed informed consent.","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study investigates the impact of letermovir prophylaxis on viral infections (including CMV, EBV, BKV, HHV-6\u002F7, RSV, ADV, HSV, etc.) following allogeneic hematopoietic stem cell transplantation in pediatric patients with EBV-associated T\u002FNK-cell lymphoproliferative diseases and refractory\u002Frelapsed EBV-related hemophagocytic lymphohistiocytosis. Additionally, we examine its effects on other transplantation complications, including engraftment failure, graft-versus-host disease (GvHD), disease relapse, thrombotic microangiopathy (TMA), overall survival (OS), post-transplant lymphoproliferative disorder (PTLD) incidence, and immune reconstitution.",[26,27,28],"EBV-associated T\u002FNK-cell Lymphoproliferative Diseases","Refractory\u002FRelapsed EBV-related Hemophagocytic Lymphohistiocytosis","Letermovir",[30,28,31,32],"EBV","EBV-associated T\u002FNK-cell lymphoproliferative diseases","refractory\u002Frelapsed EBV-related hemophagocytic lymphohistiocytosis","RECRUITING","2026-03-18",{"date":36,"type":37},"2026-03-23","ACTUAL",{"date":39,"type":37},"2025-10-01",{"date":41,"type":20},"2026-12-31",{"name":43,"class":44},"Beijing Children's Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":17,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100624629","research-on-disease-control-and-mental-health-status-of-adolescent-asthma-patients-100624629","NCT07412119","Research on Disease Control and Mental Health Status of Adolescent Asthma Patients","Inclusion Criteria:\n\n* Meet the asthma diagnostic criteria of GINA 2025\n* Age 12 to 18 years old\n* The parents and the child patient agreed and filled out the questionnaire completely.\n\nExclusion Criteria:\n\n* Children with other respiratory diseases such as bronchiectasis, bronchiolitis, cystic fibrosis and pneumonia\n* Combined with chronic diseases of other systems","12 Years",{"count":54,"type":20},460,"OBSERVATIONAL","Background: Currently in China, adolescent asthma care is characterized by both undertreatment and overtreatment. Patients in this age group may exhibit negative emotions toward disease treatment and long-term control. Insufficient disease knowledge, irregular lifestyle habits, and negative attitudes toward the disease can all reduce medication adherence, affect disease control outcomes, and thereby increase the risk of severe chronic respiratory conditions and disease burden in adulthood.\n\nObjectives: To assess disease control status in adolescent asthma patients, evaluate the psychological well-being of patients and their family members, and understand patients' self-management skills and readiness for transition to adulthood.\n\nProcedures: Eligible participants will complete a series of assessment questionnaires through the Youran Huxi mobile application, including questionnaires on asthma control, physical activity, psychological health, self-management behaviors, and transition readiness. The study period is 12 months; the baseline assessment involves one-time completion of written questionnaires with no interim follow-up visits. The study does not intervene in clinical diagnosis or treatment decisions.",[58,59],"Asthma (Diagnosis)","Adolescent - Emotional Problem",[61,62,63],"Asthma","adolescent","mental health","NOT_YET_RECRUITING","2026-02-12",{"date":67,"type":37},"2026-02-17",{"date":69,"type":20},"2026-04-01",{"date":71,"type":20},"2027-12-01",{"name":43,"class":44},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":17,"enrollmentInfo":81,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":93,"leadSponsor":94,"locationsCount":4},"100580460","control-and-treatment-of-outpatient-children-with-asthma-100580460","NCT06837584","Control and Treatment of Outpatient Children With Asthma","A Multicenter Observational Study on the Current Status of Control and Treatment of Outpatient Children With Asthma and the Types of Airway Inflammation","Inclusion Criteria:\n\n* Age between 2 and 18 years old\n* Diagnosed with asthma for more than 3 months\n* Had asthma symptoms or asthma treatment within the past 12 months.\n\nExclusion Criteria:\n\n* With other respiratory diseases such as bronchiectasis, bronchiolitis, cystic fibrosis, and pneumonia\n* Have participated in any interventional clinical studies related to asthma within the 3 months prior to enrollment in this study\n* Parents, legal representatives, or guardians do not agree to participate in this study.","2 Years",{"count":82,"type":20},42000,"The aim of this study is to comprehensively understand the disease control and management status of children with asthma in China, as well as the types of airway inflammation. The findings of this survey will help improve the asthma control level in Chinese children, facilitate future patient education, and guide rational medication use. Moreover, it will provide important evidence for health decision-making departments to better allocate and utilize medical resources.",[61],[86,87,88,89,90],"asthma","children","outpatients","management","control",{"date":67,"type":37},{"date":69,"type":20},{"date":71,"type":20},{"name":43,"class":44},{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":102,"targetDuration":4,"studyType":21,"phases":104,"briefSummary":105,"conditions":106,"keywords":110,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":45},"100579024","hetrombopag-in-promoting-platelet-engraftment-after-auto-hsct-in-children-with-neuroblastoma-100579024","NCT06818916","Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma","Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment After Autologous Hematopoietic Stem Cell Transplantation in Children With Neuroblastoma","Inclusion Criteria:\n\n* Age\\\u003C18 years old;\n* Diagnosed as neuroblastoma;\n* ECOG ≤ 2;\n* First time receiving autologous hematopoietic stem cell transplantation;\n* The subjects or their legal guardians agree to participate and sign the informed consent form.\n\nExclusion Criteria:\n\n* ALT\u002FAST \\> 3 ULN, or TBIL \\> 1.5 ULN;\n* Have experienced congestive heart failure, arrhythmia, peripheral arteriovenous thrombosis requiring medication treatment within one year prior to enrollment, or have experienced myocardial infarction or cerebral infarction within three months prior to enrollment;\n* Suffering from thromboembolic diseases;\n* Other situations that are not suitable for inclusion in the study determined by researchers.",{"count":103,"type":20},30,[23],"The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation. The main question it aims to answer is:\n\n· Does drug hetrombopag promote platelet engraftment? Participants will take hetrombopag every day for 6 weeks or until platelet \\> 100\\*10\\^9\u002FL.",[107,108,109],"Delayed Platelet Engraftment","Neuroblastoma","Autologous Hematopoietic Stem Cell Transplantation",[111,112,113,114,115],"Hetrombopag","delayed platelet engraftment","neuroblastoma","pediatrics","autologous hematopoietic stem cell transplantation","2025-11-26",{"date":118,"type":37},"2025-12-03",{"date":120,"type":37},"2024-06-30",{"date":122,"type":20},"2027-07-31",{"name":43,"class":44},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":131,"maxAge":17,"enrollmentInfo":132,"targetDuration":4,"studyType":21,"phases":134,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":150},"100608249","multicenter-pediatric-low-dose-ct-protocol-development-and-clinical-verification-100608249","NCT07199101","Multicenter Pediatric Low-Dose CT Protocol: Development and Clinical Verification","Development of a Multicenter Low-Dose CT Protocol for Children Based on Low-Dose Simulation Technology and Verification by Clinical Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged 0-17 years.\n* Pediatric patients for whom a CT examination is deemed necessary by an attending physician.\n\nExclusion Criteria:\n\n* Parents\u002Fguardians refuse to consent to low-dose CT examination.\n* Pediatric patients are in critical condition, with no time allocated for explanation of the randomized controlled trial (RCT) protocol.","0 Years",{"count":133,"type":20},2650,[23],"Children are sensitive to ionizing radiation, and there are significant regional variations in current pediatric CT radiation doses. Although there are studies on low-dose CT targeting single lesions, these studies require clear clinical indications and support from advanced equipment, making widespread promotion difficult. The establishment of low-dose CT protocols is mostly experience-based; when radiologists lack confidence in image quality, the credibility of diagnostic reports is compromised. Therefore, the development of low-dose protocols must meet the diagnostic confidence of most radiologists, enable clear visualization of key anatomical structures in clinical practice, and satisfy the requirements for disease diagnosis.\n\nThe purpose of this study is to establish a pediatric low-dose CT scanning protocol using Low-dose Simulation of CT (LDS) technology, and conduct a multicenter randomized controlled trial (RCT) in clinical settings to verify the clinical feasibility of this low-dose CT scanning protocol.",[137],"Radiation Dose Reduction",[139,140,141],"Tomography, X-ray computed","Child","radiation dose","2025-09-22",{"date":144,"type":37},"2025-09-30",{"date":146,"type":20},"2026-01-01",{"date":148,"type":20},"2027-12-31",{"name":43,"class":44},20,{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":158,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":160,"conditions":161,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":45},"100518971","the-efficacy-and-safety-of-pegylated-gh-for-the-treatment-of-short-stature-in-chinese-children-globe-reg-100518971","NCT06037473","The Efficacy and Safety of PEGylated GH for the Treatment of Short Stature in Chinese Children-GLOBE Reg","A Real-world Study of the Efficacy and Safety of PEGylated Recombinant Human Growth Hormone Injection in the Treatment of Short Stature in Chinese Children From the Global Registry for Novel Therapies For Rare Bone or Endocrine Conditions","Inclusion Criteria:\n\nPatients with endogenous growth hormone deficiency, Turner Syndrome, SGA, idiopathic short stature, etc. treated with polyethylene glycol recombinant human growth hormone injection\n\nExclusion Criteria:\n\nPatients with serious heart and lung, blood system, malignant tumors and other diseases or systemic infections, immune function is low and Persons with mental illness;",{"count":159,"type":20},2600,"In order to further observe the long-term safety and effectiveness of real-world polyethylene glycol-recombinant human growth hormone(PEG-rhGH) treatment of GHD, idiopathic short stature, and SGA in children, explore and analyze the factors affecting the efficacy of PEG-rhGH and the height prediction model after treatment, etc., collect and analyze more scientifically and rationally, and understand the situation of real-world PEG-GH treatment. A database registration study was developed.",[162,163],"Growth Hormone Treatment","Growth Disorders","2025-08-28",{"date":166,"type":37},"2025-09-04",{"date":168,"type":37},"2023-08-01",{"date":170,"type":20},"2029-08-01",{"name":43,"class":44},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":16,"minAge":131,"maxAge":17,"enrollmentInfo":178,"targetDuration":4,"studyType":21,"phases":180,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":45},"100595246","phase-4-improved-myeloablative-allogeneic-hematopoietic-stem-cell-transplantation-protocol-for-the-treatment-of-epstein-barr-virus-tnk-lymphoproliferative-disease-ebv-tnk-lpd-and-prevention-of-post-transplant-graft-versus-host-disease-100595246","NCT07029958","Improved Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Protocol for the Treatment of Epstein Barr Virus T\u002FNK Lymphoproliferative Disease (EBV-T\u002FNK LPD) and Prevention of Post Transplant Graft-versus-host Disease","Inclusion Criteria:\n\n* Meet the diagnosis of EBV-T\u002FNK lymphoproliferative disease (EBV-T\u002FNK LPD) according to the ICC2022 diagnostic criteria\n* Plan to undergo allogeneic hematopoietic stem cell transplantation (allo HSCT) in our hospital\n* Age ≤ 18 years old\n* Sign informed consent form\n* Meet one of the following conditions (haploid donors must meet one of the above conditions, unrelated donors must meet two of the above conditions): ① donor age≥40 years old; ② The donor source is unrelated donor or haplotype related female or collateral donor (brother sisters, etc.) with ≥ 1 point mismatch; ③ CD3≥4 x 10 \\^ 8\u002Fkg before transplantation; ④ The primary disease is in an HLH (hemophagocytic lymphohistiocytosis) flare or active disease phase; ⑤ ATG (or ATLG (1:2)\u002FALG (1:20) equivalent dose)\\\u003C10mg\u002Fkg\n\nExclusion Criteria:\n\n* The expected survival period for multiple organ failure is no more than 3 months\n* Not signing the informed consent form",{"count":179,"type":20},48,[181],"PHASE4","To investigate whether the addition of recombinant humanized anti-CD25 monoclonal antibody to the conventional EBV-T\u002FNK LPD conditioning regimen can prevent acute and chronic GVHD after transplantation, improve the severity of GVHD and have a corresponding impact on other related post-transplant complications such as poor engraftment, thrombotic microvascular disease, early EBV reactivation and relapse.",[184],"EBV-T\u002FNK LPD","2025-06-12",{"date":187,"type":37},"2025-06-19",{"date":189,"type":37},"2024-11-12",{"date":191,"type":20},"2029-10-30",{"name":43,"class":44},{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":4,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":16,"minAge":199,"maxAge":17,"enrollmentInfo":200,"targetDuration":17,"studyType":55,"phases":4,"briefSummary":202,"conditions":203,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":211,"locationsCount":45},"100333776","population-pharmacokinetics-of-anti-tuberculosis-drugs-in-children-with-tuberculosis-100333776","NCT03625739","Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis","Inclusion Criteria:\n\n* Children (0-18 years old) with anti-tuberculosis therapy against TB.\n* The anti-tuberculsis therapy includes drugs commonly used in children infectious diseases\n* Informed consent signed by the parents and\u002For guardians.\n\nExclusion Criteria:\n\n* Anti-tuberculosis drugs aren't involved in the therapies of children.\n* It is unable to provide complete medical records or the current condition cannot accept the study process.\n* Patients are allergic to anti-tuberculsis drugs.\n* Parents and\u002For guardians do not agree to participate in this study.","1 Day",{"count":201,"type":20},800,"This study is based on the hypothesis that the pharmacokinetics of anti-tuberculosis drugs in TB children are different from adults. The investigators aim to study the population pharmacokinetics of children receiving the anti-tuberculsis drugs for treatment of TB. In this study, the investigators will detect drug concentration in plasma by using residual blood samples of blood gas analysis and other clinical tests and employ computers for constructing population pharmacokinetic models. In addition, the investigators also want to correlate use of anti-tuberculsis drugs with treatment effectiveness and incidence of adverse effects in children. This novel knowledge will allow better and more rational approaches to the treatment of TB in children. It will also set the foundation for further studies to improve anti-tuberculosis drug therapies for children.",[204],"Tuberculosis","2018-08-14",{"date":207,"type":37},"2018-08-15",{"date":209,"type":37},"2018-07-01",{"date":41,"type":20},{"name":43,"class":44},{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":219,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":4},"100266866","registry-study-on-cystic-fibrosis-in-chinese-children-100266866","NCT02753374","Registry Study on Cystic Fibrosis in Chinese Children","Registry Study on Cystic Fibrosis in Chinese Children-a Multicenter, Prospective Cohort Study","Inclusion Criteria:\n\n* Age 0\\~18 years old\n* Any organ system symptoms consistent with CF, such as chronic sinopulmonary disease, gastrointestinal and nutritional abnormalities, obstructive azoospermia or having siblings with CF\n* CFTR dysfunction indicated by elevated sweat chloride levels ≥60 mmol\u002FL twice, or one sweat chloride levels ≥40 mmol\u002FL plus presence of two pathogenic CFTR mutations on different alleles\n* Probable CF patients with sweat chloride levels among 40\\~59 mmol\u002FL plus with presence of 0-1 pathogenic CFTR mutation\n* Consent to provide the related clinical specimen to the certain hospital\n* The guardians of the patients fully understand the purpose of the study, volunteer their children to participate in this study and sign informed consent.\n\nExclusion Criteria:\n\n* Subject will be excluded if she or he has one of the following:\n* It is unable to provide complete medical records or the current condition can not accept the diagnosis process.\n* She or he does not agree to participate in the test.",{"count":220,"type":20},100,"This study is a multicenter, prospective cohort study of patients diagnosed with cystic fibrosis, the clinical information of recruited patients, including clinical manifestations, lung function, chest imaging, quality of life and other indicators, will be followed for 10 years.",[223],"Cystic Fibrosis",[225],"cystic fibrosis, Chinese, children","2016-04-27",{"date":228,"type":20},"2016-04-28",{"date":230,"type":4},"2016-05",{"date":232,"type":20},"2030-07",{"name":43,"class":44},{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":241,"targetDuration":4,"studyType":55,"phases":4,"briefSummary":242,"conditions":243,"keywords":245,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":250,"leadSponsor":251,"locationsCount":4},"100263113","registry-study-on-primary-ciliary-dyskinesia-in-chinese-children-100263113","NCT02704455","Registry Study on Primary Ciliary Dyskinesia in Chinese Children","Registry Study on Primary Ciliary Dyskinesia in Chinese children-a Multicenter, Prospective Cohort Study","Inclusion Criteria: A included patient must be coincident with all the following items:\n\n* Age 0\\~18 years old\n* Any organ system symptoms consistent with PCD and being conform to the clinical diagnostic standard of Katergener syndrome or being coincident with at least two following specific tests:\n* Abnormal ciliary beat frequency or movement by the high speed photography microscope\n* Abnormal ciliary structure through the electronic microscopy\n* The nasal NO decreased significantly\n* The target gene mutation found\n* The clinical diagnostic criteria of the Katergener syndrome: ① bronchial expansion; ② sinusitis or nasal polyps; ③ transposition of viscera and (or) dextrocardia.\n* If all the typical clinical manifestations but only 1 specific test with positive results, can also be included in the registration of suspected PCD cases\n* Consent to provide the related clinical specimen to the certain hospital\n* The guardians of the patients fully understand the purpose of the study, volunteer their children to participate in this study, and sign informed consent.\n\nExclusion Criteria: Subject will be excluded if she or he has one of the following:\n\n* It is unable to provide complete medical records or the current condition can not accept the diagnosis process\n* She or he cannot agree to participate in the study.",{"count":220,"type":20},"This study is a multicenter, prospective cohort study of patients diagnosed with primary ciliary dyskinesia, the clinical information of recruited patients, including clinical manifestations, lung function, chest imaging, quality of life and other indicators, will be followed for 10 years.",[244],"Primary Ciliary Dyskinesia",[87],"2016-03-05",{"date":248,"type":20},"2016-03-10",{"date":230,"type":4},{"date":232,"type":20},{"name":43,"class":44},""]